Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Unpaywall

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Download PDF
Loading next page...
 
/lp/unpaywall/secukinumab-a-human-anti-interleukin-17a-monoclonal-antibody-in-yoo1e3rs5O

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Unpaywall
ISSN
0140-6736
DOI
10.1016/s0140-6736(15)61134-5
Publisher site
See Article on Publisher Site

Abstract

Journal

The Lancet – Unpaywall

Published: Sep 1, 2015

There are no references for this article.